{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:31:00Z","timestamp":1792009860141,"version":"4.4.0"},"reference-count":99,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["5T32CA009615\u201030"],"award-info":[{"award-number":["5T32CA009615\u201030"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["TL1TR001880"],"award-info":[{"award-number":["TL1TR001880"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B cell lymphoma (DLBCL), the most common type of Non\u2010Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R\u2010CHOP remains the mainstay of therapy and can achieve long\u2010term disease control in nearly 90% of patients presenting with limited\u2010stage and in up to 60% of those presenting with advanced stages. Advances on the understanding of the genetic landscape and molecular features of DLBCL have identified high\u2010risk subsets with poor outcomes to chemo\u2010immunotherapy that are actively being studied in clinical trials. Novel therapies could potentially improve outcomes for patients with high\u2010risk disease. Studies evaluating risk\u2010adapted therapy based on classification by cell of origin (COO) and molecular features are ongoing. Developments in the fields of immunotherapy, mostly with adoptive T\u2010cell therapy, have significantly improved the outcomes of patients with relapsed refractory disease. In this review, we will summarize the recent data and discuss ongoing efforts to improve DLBCL treatment in the frontline and relapsed refractory settings.<\/jats:p>","DOI":"10.1002\/ajh.26151","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T11:28:35Z","timestamp":1614857315000},"page":"617-629","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":357,"title":["2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management"],"prefix":"10.1002","volume":"96","author":[{"given":"Sandra","family":"Susanibar\u2010Adaniya","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.2383"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322362"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-212191"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-220095"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01583"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002600"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.e449"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801445"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9846"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003526"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003277"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8093"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.142752"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.5246"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14311"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7552"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.0765"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390104"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.4582"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.6929"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793984"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00999"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000875"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70481-3"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00900-7"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002567"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"issue":"1","key":"e_1_2_10_40_1","article-title":"Smart Start: rituximab, Lenalidomide, and Ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B\u2010cell lymphoma: final phase II results","volume":"134","author":"Westin JR","year":"2019","journal-title":"Blood"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3947"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30177-7"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134449"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136295"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8003"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138532"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006578"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134546"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140752"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137328"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7571"},{"issue":"1","key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-139788","article-title":"A phase Ib, open\u2010label, randomized study to assess safety and preliminary efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in addition to R\u2010CHOP in patients with newly diagnosed diffuse large B\u2010cell lymphoma: analysis of the safety run\u2010in phase","volume":"136","author":"Belada D","year":"2020","journal-title":"Blood"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.9416"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12846"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4639.4639"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000784"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.4423"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1603"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.1017"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24615"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.213"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002118"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003001"},{"issue":"1","key":"e_1_2_10_72_1","article-title":"Phase I trial of MB\u2010CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin lymphoma","volume":"136","author":"Borchmann P","year":"2020","journal-title":"Blood"},{"issue":"16","key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"CT055","DOI":"10.1158\/1538-7445.AM2020-CT055","article-title":"Abstract CT055: phase 1\/2 primary analysis of ZUMA\u20106: Axicabtagene ciloleucel (Axi\u2010Cel) in combination with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson CA","year":"2020","journal-title":"Cancer Res"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8001"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135988"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0297"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103019"},{"issue":"1","key":"e_1_2_10_79_1","article-title":"Mosunetuzumab induces complete remissions in poor prognosis non\u2010Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T\u2010cell (CAR\u2010T) therapies, and is active in treatment through multiple lines","volume":"134","author":"Schuster SJ","year":"2019","journal-title":"Blood"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135818"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136044"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-133820"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238675"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16756"},{"issue":"1","key":"e_1_2_10_91_1","article-title":"Portia: a phase 1b study evaluating safety and efficacy of Tisagenlecleucel and Pembrolizumab in patients with relapsed\/refractory diffuse large B\u2010cell lymphoma","volume":"134","author":"Jaeger U","year":"2019","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_92_1","article-title":"Checkpoint inhibitors augment CD19\u2010directed chimeric antigen receptor (CAR) T cell therapy in relapsed B\u2010cell acute lymphoblastic leukemia","volume":"132","author":"Li AM","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_10_93_1","article-title":"Sequential anti\u2010CD19 directed chimeric antigen receptor modified T\u2010cell therapy (CART19) and PD\u20101 blockade with Pembrolizumab in patients with relapsed or refractory B\u2010cell non\u2010Hodgkin lymphomas","volume":"132","author":"Chong EA","year":"2018","journal-title":"Blood"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"issue":"1","key":"e_1_2_10_95_1","article-title":"Phase 2 results of the iR2 regimen (Ibrutinib, Lenalidomide, and rituximab) in patients with relapsed\/refractory (R\/R) non\u2010germinal center B cell\u2010like (non\u2010GCB) diffuse large B\u2010cell lymphoma (DLBCL)","volume":"134","author":"Ramchandren R","year":"2019","journal-title":"Blood"},{"key":"e_1_2_10_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141447"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8073"},{"issue":"1","key":"e_1_2_10_98_1","article-title":"A phase Ia\/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs\u201012 (DTRM\u201012), in combination with Everolimus and Pomalidomide in patients with relapsed\/refractory CLL, DLBCL or other B\u2010cell lymphomas","volume":"134","author":"Mato AR","year":"2019","journal-title":"Blood"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138896"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136361"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26151","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T08:37:50Z","timestamp":1693125470000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1002\/ajh.26151"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26151","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]},"assertion":[{"value":"2021-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}